Category: piperazines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13754-38-6,1-Benzoylpiperazine,as a common compound, the synthetic route is as follows.

General procedure: General Procedure 2c (1472) 1.0 equivalent of the respective intermediate, 1.0 equivalent of 1-hydroxy-1H-benzotriazole hydrate, 2.0 equivalents of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, 3.0 equivalents of triethylamine and 1.2 equivalents of the amine were stirred in tetrahydrofuran at 25 C. for 18 h. Water was added to the reaction mixture. The solid was filtered off with suction, washed with water and diethyl ether and dried.

13754-38-6, 13754-38-6 1-Benzoylpiperazine 762654, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Bayer Pharma Aktiengesellschaft; BOTHE, Ulrich; SIEBENEICHER, Holger; SCHMIDT, Nicole; ROTGERI, Andrea; BOeMER, Ulf; RING, Sven; IRLBACHER, Horst; GUeNTHER, Judith; STEUBER, Holger; LANGE, Martin; SCHAeFER, Martina; (191 pag.)US2016/311833; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

5521-38-0, 2-(4-(4-Nitrophenyl)piperazin-1-yl)ethanol is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,5521-38-0

Reference Example 19b 2-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanol 2-[4-(4-amino-phenyl)-piperazin-1-yl]-ethanol is prepared by catalytic hydrogenation of 2[4-(4-nitrophenyl)piperazine-1-yl]-ethanol (prepared as in Reference Example 19a) as described in Reference Example 13b

5521-38-0 2-(4-(4-Nitrophenyl)piperazin-1-yl)ethanol 2763936, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Pierson, Edward; Sohn, Daniel; Haeberlein, Markus; Davenport, Timothy; Chapdelaine, Marc; Horchler, Carey; McCauley, John P.; US2003/13708; (2003); A1;; ; Patent; Chapdelaine, Marc; Davenport, Timothy; Haeberlein, Markus; Horchler, Carey; McCauley, John; Pierson, Edward; Sohn, Daniel; US2004/110745; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.692058-21-2,1-Boc-4-(2,2,2-trifluoroethyl)piperazine,as a common compound, the synthetic route is as follows.

Hydrogen chloride gas was bubbled through a solution of tert-butyl 4- (2, 2, 2-TRIFLUOROETHYLPIPERAZINE-1-CARBOXYLATE (8 g) in ethyl acetate (50 ml) during 1.5 hours. A precipitate formed as carbon dioxide gas was evolved. The precipitate was collected by filtration, washed with ethyl acetate and dried under vacuum. There was thus obtained 1- (2, 2, 2-trifluoroethyl) piperazine hydrochloride (7 g); NMR Spectrum : (DMSOd6 and CF3CO2D) 2.85 (m, 4H), 3.1 (m, 4H), 3.35 (q, 2H), 692058-21-2

The synthetic route of 692058-21-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2004/41829; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103-76-4,N-(2-Hydroxyethyl)piperazine,as a common compound, the synthetic route is as follows.

To a solution of 1-(2-hydroxyethyl) piperazine (1.0g, 7.686mmol) in dichloromethane (25mL) were added di-tert butyl dicarbonate (2.013g, 9.223mmol) and triethylamine (TEA, 2.130g, 15.372mmol). The reaction mixture was stirred at room temperature for 12h, then washed with 3% HCl aqueous (2¡Á50mL), saturated NaHCO3 aqueous (2¡Á50mL), brine (2¡Á50mL). The resulting organic layer wasdried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with dichloromethane/methanol (40:1) to form 1-Boc-4-(2-hydroxyethyl)-piperazine a colorlessoil (1.592g, 90% yield).

103-76-4, As the paragraph descriping shows that 103-76-4 is playing an increasingly important role.

Reference£º
Article; Hu, Caijuan; Su, Hao; Luo, Jinghan; Han, Li; Liu, Qingyin; Wu, Wenxi; Mu, Yu; Guan, Peipei; Sun, Tiemin; Huang, Xueshi; Bioorganic and Medicinal Chemistry; vol. 26; 23-24; (2018); p. 6035 – 6049;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

129799-08-2, 1-tert-Butyl 3-methyl piperazine-1,3-dicarboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of /ert-butyl (2-oxoethyl)carbamate (4.89 g, 30.7 mmol) in 1,2- dichloroethane (50 mL) was added to a solution of l-(tert-butyl) 3-methyl piperazine- 1,3- dicarboxylate (5 g, 20.5 mmol) in l,2-dichloroethane (25 mL). The solution stirred at 25 C under nitrogen atmosphere for 30 min. Sodium triacetoxyborohydride (8.69 g, 41.0 mmol) was added, and the resulting mixture stirred at 25 C for 15 h. The reaction was quenched by the addition of water (50 mL) at 25 C. The resulting mixture was extracted with dichloromethane (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, and the solids were filtered out. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (eluting with 1 : 1 ethyl acetate/petroleum ether) to afford l-ter/-butyl 3- methyl 4-(2-(/er/-butoxycarbonylamino)ethyl)piperazine-l,3-dicarboxylate as yellow oil (5.1 g, 64%). LCMS (ES, m/z): 388 [M+H]+.

129799-08-2, The synthetic route of 129799-08-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FORMA THERAPEUTICS, INC.; MARTIN, Matthew W.; BUCKMELTER, Alexandre Joseph; (158 pag.)WO2019/222468; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

31166-44-6, 1-Cbz-Piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

PIPERAZINE-L-CARBOXYLIC acid benzyl ester (1.03 g, 4. 68 mmol. 1.0 eq. ) and 4- TETRAIDROPIRANIL aldeide (0.8 mg, 7. 0 mmol, 1. 5 eq. ) are dissolved in 20 ml of anhydrous DCM. Na (OAC) 3BH (1. 48 g, 7.0 mmol, 1. 5 eq.) are added to this opalescent solution. The reaction is left under magnetic stirring and under a nitrogen atmosphere at room temperature for 2 hours. When the reaction is completed the solvent is removed by evaporation under reduced pressure. AcOEt (20 mL) and a IN solution OF NAOH (20 mL) are added and the biphasic system transferred to a separatory funnel. The phases are separated and the organic phase is washed with water and brine, dried on NASO,}, FILTERED and the solvent removed by evaporation under reduced pressure. 4- (Tetrahydro-pyran-4-ylmethyl)-piperazine-1-carboxylic acid benzyl ester (20) is obtained as a colourless oil (1. 3 g, 4. 08 mmol, yield = 87percent) H1 NMR (No., DMSO-D6, 300 MHZ) : 1.10 (qd, 2H, He, J= 6.3, 13.5 Hz) ; 1.59 (d, 2H, HD, J = 12. 6 Hz); 1.72 (M, 1H, HE) ; 2.30 (m, 4H, Hh); 2.63 (m, 2H, Hl); 3.23-3. 37 (m, 4H+2H, Hg + Hb), 3.80-3. 84 (M, 2H, Ha), 5.07 (s, 2H, PHCH2) ; 7.31-7. 40 (M, 5H, ArH)., 31166-44-6

31166-44-6 1-Cbz-Piperazine 643495, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; MENARINI RICERCHE S.P.A.; WO2004/94412; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.39539-66-7,4-Methylpiperazine-1-carbonyl chloride,as a common compound, the synthetic route is as follows.

Example 18 : 2,3-Dichloro-N-((1S,2S)-1-{[(4-methylpiperazin-1-yl)carbonyl]amino}-2,3- dihydro-lH-inden-2-yl)-4H-thienof3, 2-blpyrrole-5-carboxamide; To a solution of N-[(1S,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]-2,3-dichloro-4H- thieno [3, 2-b] pyrrole-5-carboxamide (Method 9, 240 mg, 0. 5 mmol) and Et3N (101 mg, 1. 0 mmol) in DCM (4 mL) was added a solution of 4-methyl-1-piperazine carbonyl chloride (100 mg, 0. 5 mmol) in DCM (1 mL). The reaction was stirred at ambient temperature for 2 hours, washed with saturated Narc03 (1 mL), water (1 mL), brine (1 mL) and dried (MgS04). The volatiles were removed by evaporation under reduced pressure to give the title compound (110 mg, 45%) as a foam. MS m/z (M-H)-491.

39539-66-7, As the paragraph descriping shows that 39539-66-7 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2003/74531; (2003); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.74879-18-8,(S)-(+)-2-Methylpiperazine,as a common compound, the synthetic route is as follows.

74879-18-8, (S)-2-methylpiperazine (5.00 g, 49.9 mmol) was dissolved in DCM (150 mL). A solution of boc anhydride (5.47 g, 25.0 mmol) in DCM (50 mL) was added dropwise at 0 C. The reaction mixture was stirred at rt for 2 h. The solution was filtered and concentrated under reduced pressure. Water (100 mL) was added to the residue and it was filtered again. The filtrate was saturated with K2CO3 and extracted with Et2O (3¡Á150 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide 4.92 g title compound (49%) as a solid. 1H NMR (300 MHz, CDCl3) delta ppm 1.03 (d, J=6.3 Hz, 3H) 1.45 (s, 9H) 1.53 (br. s, 1H) 2.38 (t, J=11.8 Hz, 1H) 2.65-2.72 (m, 1H) 2.74-2.76 (m, 2H) 2.92-2.95 (m, 1H) 3.92 (br. s, 2H).

As the paragraph descriping shows that 74879-18-8 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; US2010/216812; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.74879-18-8,(S)-(+)-2-Methylpiperazine,as a common compound, the synthetic route is as follows.

74879-18-8, In a sealed tube, 2-(2,8-dimethylimidazo[l,2-b]pyridazin-6-yl)-7-fluoro-pyrido[l,2- a]pyrimidin-4-one (Intermediate 2; 33 mg, 0.107 mmol), and (S)-2-methylpiperazine (43 mg, 0.427 mmol, 4.0 eq.) were stirred in DMSO (2 mL) at 120C overnight. The solvent was removed under high vacuum. The residue was taken up in CH2CI2and washed with an aqueous saturated solution of NaHC03. The organic layer was separated and dried over Na2S04and concentrated in vacuo. The crude was purified by column chromatography (S1O2,CH2Cl2/MeOH=95/5 to 90/10) to afford the title product (18 mg, 43%) as a light yellow solid. MS m/z 390.3 [M+H+].

74879-18-8 (S)-(+)-2-Methylpiperazine 2734219, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; MCCARTHY, Kathleen Dorothy; METZGER, Friedrich; RATNI, Hasane; (76 pag.)WO2017/81111; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.

According to scheme I, to a 250-mL flash were added Compound Ia-1, i.e. 2,6-dichloro-3,5-dimethoxyaniline (10mmol) and AcOH (24ml), and added dropwisely under an ice-bath a solution of sodium nitrite (15mmol) in sulphuric acid (5.8ml) . The mixture was stirred at 25C until the solution became clear. The resulting dark yellow solution was poured into 150ml of an ice-water, and urea (6mmol) was added. The mixture was stirred and filtered. An aqueous solution of potassium iodide (15mmol) was added to the above dark-yellow solution. The mixture was heated at 85C for 2 hours, and cooled to room temperature. NaHSO3 (3.4 mmol) was added, and the mixture was stirred for 10 minutes. The resulting yellow solid was filtered, dried, and separated by column chromatography to produce Compound Ib-1 (8mmol). Compound Ib-1 (4 mmol), and Compound A-1, i.e. 4-piperidinone ethylene ketal (6 mmol) were dissolved in 50ml toluene, and palladium acetate (0.4 mmol), BINAP (0.48 mmol), and cesium carbonate (18 mmol) were added. The mixture was refluxed under the nitrogen protection for 3 days, and separated by column chromatography to produce Compound Ic-1. Compound Ic-1 (2.5 mmol) was dissolved in 10ml THF, and 10% aqueous H2SO4 solution (10ml) was added. The mixture was heated at 60C overnight, and separated by column chromatography to produce Compound Id-1. Compound Id-1 (1.0 mmol) was dissolved in 10ml dioxane, and DMF.DMA (6.0 mmol) and triethylamine (1.0 mmol) were added. The mixture was refluxed under the nitrogen protection for 2 days, and separated by thin layer chromatography to produce Compound Ie-1. Compound B-1, i.e., 1-fluoro-4-nitrobenzene (10 mmol) was dissolved in 20ml DMF, and C-1, i.e., N-ethylpiperazine (11 mmol), and potassium carbonate (30 mmol) were added. The mixture was reacted at 70C overnight. After cooling, the mixture was poured into ice-water, and filtered to produce Compound If-1. Compound If-1 (10 mmol) was dissolved in 20ml methanol or ethanol, and palladium/carbon (1mmol) was added. The mixture was hydrogenated at room temperature for 7 hours. The mixture was separated by column chromatography to produce Compound Ig-1. Compound Ig-1 (2.6 mmol) was dissolved in 10ml dioxane, and cyanoamine (2.73 mmol), and concentrated hydrochloric acid (3.9 mmol) were added. The mixture was stirred under reflux overnight to produce Compound Ih-1. Compound Ie-1 (1mmol) and Compound Ih-1 (1.05mmol) were dissolved in 8ml ethanol, and sodium acetate (2mmol) and triethylamine (1.05mmol) were added. The mixture was stirred under flux for 7 hours, ethanol concentrated, and water and dichloromethane were added. The organic phase was separated, dried over anhydrous sodium sulphate, and separated by thin layer chromatography to produce Compound I-1 (0.1mmol) in a yield of 10%.H1-NMR(deuterated MeOH) : delta8.11(s, 1H), delta7.56(d, 2H), delta6.99(d, 2H), delta6.72(s, 1H), delta4.25(s, 2H), delta3.93(s, 6H), delta3.56(t, 2H), delta3.23(m, 4H), delta2.92(t, 2H), delta2.8(m, 4H), delta2.64(m, 3H), delta1.2(t, 3H). ESI(+)m/z: 543, 115619-01-7

The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shanghai Allist Pharmaceutical and Medical Technology Corporations; KUANG, Rongren; (39 pag.)EP3466948; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics